Ranibizumab biosimilar/polyethyleneglycol-conjugated gold nanoparticles as a novel drug delivery platform for age-related macular degeneration
作者： Akihiro Hoshikawa , Tatsuaki Tagami , Chisa Morimura , Kaori Fukushige , Tetsuya Ozeki
DOI: 10.1016/J.JDDST.2017.01.004
关键词:
摘要: Abstract Ranibizumab is a first-line therapy against age-related macular degeneration. For further improvement of ranibizumab-based treatment, we developed ranibizumab biosimilar (Mab)/polyethyleneglycol (PEG)-conjugated small gold nanoparticles (core size: approximately 5 nm) as novel platform (Mab) delivery. Mab/PEG-conjugated were successfully prepared, and the particles characterized by transmission electron microscopy dynamic light scattering method. The mean diameters PEG-conjugated varied using different lengths PEG chain (5 kDa 10 kDa). Mab conjugation efficiency was optimized changing amount in preparation, which showed high (>70%). We found that effectively inhibited tube formation human umbilical vein endothelial cells based on Matrigel in vitro . without unexpectedly. did not affect cell proliferation cells. These results suggest can be used good colloidal formulation angiogenesis-related diseases local sites such
sci-hub.se 参考文章(22)
Rieke Alten, Bruce N. Cronstein, Clinical trial development for biosimilars. Seminars in Arthritis and Rheumatism. ,vol. 44, ,(2015) , 10.1016/J.SEMARTHRIT.2015.04.002
Peter J. Polverini, Angiogenesis in health and disease: insights into basic mechanisms and therapeutic opportunities. Journal of Dental Education. ,vol. 66, pp. 962- 975 ,(2002) , 10.1002/J.0022-0337.2002.66.8.TB03565.X
Mathias Brust, Merryl Walker, Donald Bethell, David J. Schiffrin, Robin Whyman, Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid-liquid system Journal of The Chemical Society, Chemical Communications. pp. 801- 802 ,(1994) , 10.1039/C39940000801
K Jin Kim, Bing Li, Jane Winer, Mark Armanini, Nancy Gillett, Heidi S Phillips, Napoleone Ferrara, None, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature. ,vol. 362, pp. 841- 844 ,(1993) , 10.1038/362841A0
Priyabrata Mukherjee, Resham Bhattacharya, Ping Wang, Ling Wang, Sujit Basu, Janice A. Nagy, Anthony Atala, Debabrata Mukhopadhyay, Shay Soker, Antiangiogenic properties of gold nanoparticles. Clinical Cancer Research. ,vol. 11, pp. 3530- 3534 ,(2005) , 10.1158/1078-0432.CCR-04-2482
Nilesh M. Pandya, Naranjan S. Dhalla, Dev D. Santani, Angiogenesis : a new target for future therapy Vascular Pharmacology. ,vol. 44, pp. 265- 274 ,(2006) , 10.1016/J.VPH.2006.01.005
Sophie J. Bakri, Melissa R. Snyder, Joel M. Reid, Jose S. Pulido, Mohamed K. Ezzat, Ravinder J. Singh, Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. ,vol. 114, pp. 2179- 2182 ,(2007) , 10.1016/J.OPHTHA.2007.09.012
Yunlong Pan, Qing Wu, Li Qin, Jiye Cai, Bin Du, Gold Nanoparticles Inhibit VEGF165-Induced Migration and Tube Formation of Endothelial Cells via the Akt Pathway BioMed Research International. ,vol. 2014, pp. 418624- 418624 ,(2014) , 10.1155/2014/418624
Hwiwon Lee, Min-Young Lee, Suk Ho Bhang, Byung-Soo Kim, Yun Seop Kim, Ji Hyeon Ju, Ki Su Kim, Sei Kwang Hahn, Hyaluronate–Gold Nanoparticle/Tocilizumab Complex for the Treatment of Rheumatoid Arthritis ACS Nano. ,vol. 8, pp. 4790- 4798 ,(2014) , 10.1021/NN500685H
Jaclyn L. Kovach, Stephen G. Schwartz, Harry W. Flynn, Ingrid U. Scott, Anti-VEGF Treatment Strategies for Wet AMD. Journal of Ophthalmology. ,vol. 2012, pp. 786870- 786870 ,(2012) , 10.1155/2012/786870